username: password:     Join free | Forgot password
Add to favorites    中文
home > news and events
Medix Biochemica announces European launch of antibody production services at MEDICA 2013

Clicks:303 Date:11/15/13

Advanced antibody production services for exceptional IVD assays

Kauniainen, Finland 鈥 14 November 2013. Medix Biochemica, producer of monoclonal antibodies for the global IVD industry and diagnostic rapid tests, is presenting its MedixMAB™ by Design and MedixMAB™ Manufacturing antibody production services to the European market at MEDICA 2013, Dusseldorf, Germany, 20-23 November, Hall 3, Stand F44.

With 30 years of antibody expertise, Medix offers customised services for the in vitro generation of high-performance recombinant or monoclonal antibodies and Fab fragments for superior IVD assays. With all antibodies produced to the strictest international quality standards (ISO 9001, ISO 13485 and FDA QSR) the services equip manufacturers with a competitive advantage, helping to increase sales revenue without the need to invest in costly production facilities and expertise.

The advanced phage display recombinant production technology of the MedixMAB by Design service enables the targeting of a broader range of antigens than possible in vivo, including poorly immunoreactive and toxic compounds, with production available on a range of scales (mg-kg). As a rapid alternative to producing full length monoclonal antibodies, Fab fragments can be generated in just three months, and greatly enhance specificity and sensitivity of IVD assays in solid-phase applications.

MedixMAB Manufacturing presents a cost-effective and flexible monoclonal antibody outsourcing option for IVD manufacturers. Completely tailored to the needs of the project, the service offers the option to outsource all or just parts of the manufacturing process to the scale and deadlines required. Medix Biochemica offers a secure and stable contract manufacturing option, and is a trusted partner for the world鈥檚 leading IVD manufacturers.

Medix Biochemica announces European launch of antibody production services at MEDICA 2013

All the MedixMAB services come with a personal project manager assigned to each project, providing full consultation and support throughout the process, tailoring the services to each individual need.

For more information, visit us at MEDICA, Hall 3, Stand F44, or see the website.

About Medix Biochemica
Medix Biochemica is a Finnish biotechnology company that develops, produces and markets monoclonal antibodies for IVD industry and diagnostic rapid tests for human healthcare worldwide. The company offers a flexible production scale, consistent quality from batch to batch and competitive pricing, with an efficient global delivery service. The business encompasses four main activities:

路MedixMAB monoclonal antibodies for IVD applications - industrial scale manufacturing
路MedixMAB Manufacturing - contract manufacturing service
路MedixMAB by Design - customised recombinant antibodies
路Actim rapid tests for human healthcare - particularly for women鈥檚 health
Related News>> more
  • TELSTAR HAS INTRODUCED ionHP BIODECONTAMINATION TECHNOLOGY FOR ASEPTIC SYSTEMS4/23/2014
  • ISPE Singapore Conference & Exhibition 2014 & Healthcare Facilities Asia4/17/2014
  • 5th CSHA Symposium: Structural Biology - From Atoms to Cells4/14/2014
  • RephiLe successfully presented at analytica 20144/10/2014
  • Biotech China Show Preview4/9/2014
  • Biotech China to Showcase Industrial Parks4/9/2014
  • CSHA 2014:Liver Metabolism, Diseases and Cancer4/3/2014
  • An Interview with Pall's Global Vaccine Market Manager Annelies Onraedt3/28/2014
  • 2nd Annual Single Cell Genomics and Transcriptomics Asia Congress3/28/2014
  • 4th Annual Next Generation Sequencing Asia Congress3/28/2014
  • advertisement

    Copyright(C) 2006-2014 bio-equip    E-mail:web@bio-equip.cn   娌狪CP澶06040519鍙